Drugs / AzaFol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06335888 | Feb 2025 → May 2029 expected | temporal arteritis | Insel Gruppe AG, University Hospital Bern | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AzaFol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06335888 ↗ |
| Known as | 3'-Aza-2'-\[18F\]Fluoro-Folic Acid | “3'-Aza-2'-\[18F\]Fluoro-Folic Acid (AzaFol) is a nuclear tracer targeting FRβ.” NCT06335888 ↗ |
| Modality | Diagnostic / imaging agent | “AzaFol is a nuclear tracer targeting FRβ.” NCT06335888 ↗ |